Volasertib

Generic Name: Volasertib

Drug Type: Small Molecule

Chemical Formula: C_₃₄H_₅₀N_₈O_₃

CAS Number: 755038-65-4

Unique Ingredient Identifier: 6EM57086EA

Background: Volasertib has been used in trials studying the treatment of Leukemia, Neoplasms, Leukemia, Myeloid, Acute, Myelodysplastic Syndromes, and Leukemia, Monocytic, Acute, among others.

Clinical Trials

Volasertib Combined With Induction Chemotherapy in Acute Myeloid Leukemia

Phase 1

Withdrawn

Conditions: AML

Interventions: Drug: Volasertib
Drug: Cytarabine
Drug: Idarubicin
Procedure: Bone Marrow Biopsy

First Posted Date: 2016-09-19

Last Posted Date: 2018-05-04

Lead Sponsor: Massachusetts General Hospital

Registration Number: NCT02905994

Locations: 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Massachusetts general Hospital, Boston, Massachusetts, United States

Study of Volasertib and Belinostat in Patients With Relapsed and Refractory Aggressive B-cell and T-cell Lymphomas

Phase 1

Withdrawn

Conditions: Relapsed and Refractory Aggressive B- and T-cell Lymphomas
Lymphoma

Interventions: Drug: volasertib
Drug: belinostat

First Posted Date: 2016-08-22

Last Posted Date: 2017-12-22

Lead Sponsor: Yale University

Registration Number: NCT02875002

Locations: 🇺🇸
Yale Cancer Center, New Haven, Connecticut, United States
🇺🇸
Massey Cancer Center, Richmond, Virginia, United States
🇺🇸
Sidney Kimmel Comprehensive Cancer, Baltimore, Maryland, United States

Volasertib and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia

Phase 1

Withdrawn

Conditions: Recurrent Adult Acute Lymphoblastic Leukemia
Refractory Adult Acute Lymphoblastic Leukemia

Interventions: Other: Laboratory Biomarker Analysis
Other: Pharmacological Study
Drug: Vincristine Sulfate Liposome
Drug: Volasertib

First Posted Date: 2016-08-10

Last Posted Date: 2016-12-15

Lead Sponsor: Northwestern University

Registration Number: NCT02861040

Locations: 🇺🇸
Stanford University, Palo Alto, California, United States
🇺🇸
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States

Ph1 Volasertib Plus Romidepsin in R/R PTCL and CTCL

Phase 1

Withdrawn

Conditions: PTCL
CTCL

Interventions: Drug: Volasertib
Drug: Romidepsin

First Posted Date: 2016-05-02

Last Posted Date: 2016-12-01

Lead Sponsor: Anne Beaven, MD

Registration Number: NCT02757248

A Study to Find a Safe Dose of Volasertib Given in Addition to Standard Salvage Chemotherapy in Children (Age 3 Months to Less Than 18 Years) With Acute Myeloid Leukaemia, in Whom Front-line Chemotherapy Failed

Phase 1

Withdrawn

Conditions: Leukemia, Myeloid, Acute

Interventions: Drug: Volasertib

First Posted Date: 2016-03-29

Last Posted Date: 2017-01-27

Lead Sponsor: Boehringer Ingelheim

Registration Number: NCT02722135

Locations: 🇧🇪
Boehringer Ingelheim Investigational Site, Gent, Belgium

Trial of Volasertib With or Without Azacitidine in Patients With Myelodysplastic Syndromes

Phase 1

Terminated

Conditions: Myelodysplastic Syndromes

Interventions: Drug: Volasertib
Drug: Azacitidine

First Posted Date: 2016-03-29

Last Posted Date: 2018-08-09

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 1

Registration Number: NCT02721875

Locations: 🇯🇵
University of Fukui Hospital, Fukui, Yoshida-gun, Japan

A Study of Volasertib Plus Induction Chemotherapy for Acute Myeloid Leukemia

Phase 1

Withdrawn

Conditions: Leukemia, Myelomonocytic, Acute
Leukemia, Myeloid, Acute
Leukemia, Monocytic, Acute
Leukemia, Erythroblastic, Acute
Leukemia, Megakaryoblastic, Acute

Interventions: Drug: Volasertib
Drug: Idarubicin
Drug: Cytarabine

First Posted Date: 2015-08-18

Last Posted Date: 2017-04-05

Lead Sponsor: University of Alberta

Registration Number: NCT02527174

Locations: 🇨🇦
University of Alberta Hospital, Edmonton, Alberta, Canada
🇨🇦
Tom Baker Cancer Centre, Calgary, Alberta, Canada

BI 6727 Administered Intravenously Every 3 Weeks in Patients With Solid Tumours

Phase 1

Completed

Conditions: Neoplasms

Interventions: Drug: BI 6727

First Posted Date: 2014-10-24

Last Posted Date: 2023-10-03

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 65

Registration Number: NCT02273388

Locations: 🇧🇪
1230.1.32002 Boehringer Ingelheim Investigational Site, Brussels, Belgium
🇧🇪
1230.1.32001 Boehringer Ingelheim Investigational Site, Leuven, Belgium

Volasertib in Combination With Azacitidine in Japanese Patients With Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

Phase 1

Completed

Conditions: Myelodysplastic Syndromes
Leukemia, Myelomonocytic, Chronic

Interventions: Drug: Azacitidine
Drug: Volasertib

First Posted Date: 2014-07-28

Last Posted Date: 2018-07-30

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 5

Registration Number: NCT02201329

Locations: 🇯🇵
Boehringer Ingelheim Investigational Site, Tokyo, Sinagawa-ku, Japan

Trial of Intensive Chemotherapy With or Without Volasertib in Patients With Newly Diagnosed High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)

Phase 2

Terminated

Conditions: High-risk Myelodysplastic Syndrome (MDS)
Acute Myeloid Leukemia (AML)

Interventions: Drug: Cytarabine
Drug: Volasertib
Drug: Daunorubicin
Drug: Mitoxantrone

First Posted Date: 2014-07-23

Last Posted Date: 2018-02-28

Lead Sponsor: University of Ulm

Target Recruit Count: 6

Registration Number: NCT02198482

Locations: 🇩🇪
Hospital Aschaffenburg, Aschaffenburg, Germany
🇩🇪
Helios Hospital Bad Saarow, Bad Saarow, Germany
🇩🇪
Vivantes Hospital Neukölln, Berlin, Germany

and more 42 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy